首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >Efficacy and Safety of a Chinese Herbal Medicine Formula (RCM-104) in the Management of Simple Obesity: A Randomized Placebo-Controlled Clinical Trial
【2h】

Efficacy and Safety of a Chinese Herbal Medicine Formula (RCM-104) in the Management of Simple Obesity: A Randomized Placebo-Controlled Clinical Trial

机译:中草药配方(RCM-104)在单纯性肥胖管理中的功效和安全性:一项随机安慰剂对照的临床试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objective. This study was to evaluate the efficacy and safety of a Chinese herbal medicine formula (RCM-104) for the management of simple obesity. Method. Obese subjects aged between 18 and 60 years were selected for 12-week, double-blind, randomized, placebo-controlled trial. Subjects were randomly assigned to take 4 capsules of either the RCM-104 formula (n = 59) or placebo (n = 58), 3 times daily for 12 weeks. Measures of BW, BMI and WC, HC, WHR and BF composition were assessed at baseline and once every four weeks during the 12 week treatment period. Results. Of the 117 subjects randomised, 92 were included in the ITT analysis. The weight, BMI and BF in RCM-104 group were reduced by 1.5 kg, 0.6 kg/m2 and 0.9% and those in the placebo group were increased by 0.5 kg, 0.2 kg/m2 and 0.1% respectively. There were significant differences in BW and BMI (P < 0.05) between the two groups. Eleven items of the WLQOQ were significantly improved in the RCM-104 group while only 2 items were significantly improved in the placebo group. Adverse events were minor in both groups. Conclusion. RCM-104 treatment appears to be well tolerated and beneficial in reducing BW and BMI in obese subjects.
机译:目的。这项研究旨在评估中草药配方(RCM-104)治疗单纯性肥胖的有效性和安全性。方法。选择年龄在18至60岁之间的肥胖受试者进行为期12周的双盲,随机,安慰剂对照试验。受试者被随机分配服用4粒RCM-104配方(n = 59)或安慰剂(n = 58)胶囊,每天3次,共12周。在基线时以及在12周治疗期间每四周评估一次BW,BMI和WC,HC,WHR和BF组成的指标。结果。在随机分配的117名受试者中,有92名被纳入ITT分析。 RCM-104组的体重,BMI和BF分别降低1.5 kg,0.6 kg / m 2 和0.9%,而安慰剂组的体重,BMI和BF分别升高0.5 kg,0.2 kg / m 2 和0.1%。两组之间的体重和体重指数有显着差异(P <0.05)。 RCM-104组的WLQOQ有11项显着改善,而安慰剂组只有2项显着改善。两组的不良事件均较小。结论。 RCM-104治疗似乎具有良好的耐受性,并且在降低肥胖受试者的BW和BMI方面是有益的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号